– USA, WA – OtoNexus Medical Technologies, Inc. today announced the appointment of Chris Rivera to its Board of Directors, strengthening the leadership and positioning for success in the life sciences industry.
About Chris Rivera
Chris Rivera has a demonstrated track record of success in building and exiting life sciences companies throughout his career. He is the Chairman, CEO, and President of EMulate Therapeutics and was the founder and CEO of Hyperion Therapeutics, which Horizon Pharma acquired in 2015. He has held executive leadership roles in many successful companies, including Tercica, Cephalon, Centicor, and Genzyme Therapeutics.
Mr. Rivera has extensive experience in building successful life sciences companies, including leadership, board directorship, business strategy, funding/financing, product launch, manufacturing, distribution, commercial infrastructure, reimbursement, FDA market clearance, licensing, and exit via acquisition and IPO.
Mr. Rivera also served as President and CEO of Life Science Washington. He helped build the life sciences industry in Washington state and mentored over 400 life science start-up companies. He has also been recognized as a state and national leader through his appointments as co-Chair for the Governor’s life science and global health advisory committee, the Governor’s Higher Education Task Force, the Washington Global Health Funding Commission, and Chairman of the Board for the National Council of State Bioscience Associations.
Having started his career as an audiologist, Mr. Rivera is particularly interested in OtoNexus’ innovative technology and has been an active supporter of the company because of his direct experience in the field. “I am excited to join the OtoNexus Board of Directors and work with the team to advance its innovative technology,” said Chris. “I share OtoNexus’ philosophy on leadership and building high-performing teams. The company’s innovative diagnostic tools and commitment to improving patient outcomes align with my own values and experience. I look forward to working with the team to drive growth and success.”
About OtoNexus Medical Technologies Inc.
OtoNexus has developed the world’s first hand-held medical device with miniaturized ultrasound technology to assess middle ear infections instantly and accurately. In less than two seconds, physicians can evaluate middle ear infections and know whether antibiotic therapy is appropriate. This definitive test will provide physicians with the information they need to minimize the use of antibiotics, improve patient outcomes and reduce the cost of care.
For more information: https://otonexus.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
